April 28, 2022
This week, SNMMI and over 70 organizations sent a letter to House Energy and Commerce and Ways and Means Committee Leadership requesting a hearing on the Facilitating Innovative Nuclear Diagnostics (FIND) Act.
In July 2021, Reps. Scott Peters, Bobby Rush, Greg Murphy, and Neal Dunn introduced the FIND Act (H.R. 4479), legislation that would significantly expand patient access to advanced nuclear diagnostic imaging technologies. The bill aims for a legislative fix to CMS's bundling of diagnostic radiopharmaceuticals in the hospital outpatient space after a 3-year pass-through period post-FDA approval. SNMMI and its coalition partners, the Medical Imaging & Technology Alliance (MITA) and the Council on Radionuclides and Radiopharmaceuticals (CORAR)—in additional to dozens of patient advocacy organizations—praised the introduction.
The FIND Act addresses structural issues in the packaging methodology used in the Medicare outpatient hospital setting by directing the Department of Health and Human Services (HHS) to pay separately for all diagnostic radiopharmaceuticals with a cost threshold per day of $500. If passed, this bill would give patients greater access to a wide range of diagnostic radiopharmaceuticals that can better detect conditions such as heart disease, Alzheimer's and Parkinson’s disease, breast and prostate cancer, and neuroendocrine tumors. This legislation would also help providers better manage costs while delivering more targeted and cost-efficient care. If passed, patients would not be responsible for the 20% drug co-payment. The bill is also budget-neutral.
For more information on the FIND Act, please click here.